Dendritic cell and B cell response to Campylobacter predisposing to Guillain-Barré syndrome.

Dendritic cell and B cell response to Campylobacter predisposing to Guillain-Barré syndrome. - DC/B response in GBS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34577

Enrollment

Registered

2010-10-04

Start date

2011-05-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute inflammatory demyelinating polyneuropathy no lay-term

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy controls (partners, non-related family members or friends of the (ex)-GBS patients): - Age 18 years or older - Written informed consent given by the subject. Ex-GBS patients: - Fulfilling the diagnostic criteria for GBS (Asbury, 1990) - Culture-proven and/or positive serology for C. jejuni (at time of diagnosis). - Current age: 18 years or older - Diagnosis of GBS was made after 1987 and at least one year before inclusion in the study. - Patients were treated at the ward of the department of Neurology, Erasmus MC, or at the Sophia Children*s Hospital. - Written informed consent was given by the subject.

Exclusion criteria

Exclusion criteria: Both groups: - Additional diseases or disorders at the time of diagnosis or at time of blood sampling that may influence the endpoints: *autoimmune diseases (like multiple sclerosis, psoriasis, Crohn*s disease, ulcerative colitis, hepatitis, rheumatoid arthritis, SLE and other systemic diseases) *acute and chronic infectious diseases (like infectious mononucleosis, HIV/AIDS) *malignancies (not in remission);- Medicines at time of blood sampling that may affect endpoints (i.e. inflammatory processes): *NSAIDs, corticosteroids, cyclosporine *Cytostatic compounds *Cytokines (analogues) and biologicals *Intravenous immunoglobulins.

Design outcomes

Primary

Measure	Time frame
The DC response to LOS as determined by: 1) B-cell proliferative capacity; 2) production of cytokines, including interferon (IFN)-β, interleukin (IL)-6, IL-10, IL-12 and tumor necrosis factor (TNF)-a; and 3) expression of differentiation markers, including CD40, CD80, CD86 and HLA-DR.	—

Secondary

Measure	Time frame
Gene expression profile of DC stimulated with C. jejuni LOS of (ex-)GBS patients and healthy controls.	—

Countries

Netherlands

Outcome results